BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
BioPharm Executive - Golden Handshakes
Mylan Inc. (MYL)'s Overseas Move Will Lower Tax Rate 7/23/2014
AbbVie (ABBV) Finally Clinches Shire For $54 Billion 7/21/2014
Novartis AG (NVS), Google Inc. Strike Smart Contact Lenses Pact 7/15/2014
Genentech (RHHBY) To Pay Up To $1.7 Billion For San Diego Biotech Firm Seragon Pharmaceuticals 7/7/2014
Massachusett's bluebird bio (BLUE) Snaps Up Pregenen For Up To $139.9 Million 7/2/2014
Tapping University of California, San Francisco (UCSF) Invention, Roche (RHHBY) To Partner With San Diego Startup Inception Sciences, Versant Ventures To Form New Multiple Sclerosis Company 6/24/2014
Major Drugmakers Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK). And Johnson & Johnson (JNJ) Link Up With Academia In Huge $27 Million UK Dementia Project 6/20/2014
AstraZeneca PLC (AZN) Beefs Up Pipeline With $232 Million Synairgen plc Asthma Deal 6/12/2014
Merck & Co., Inc. (MRK) Snags Cambridge's Idenix Pharmaceuticals, Inc. (IDIX) For $3.85 Billion 6/11/2014
Adaptimmune Ltd., GlaxoSmithKline (GSK) Strike $350 Million Cancer Immunotherapy Pact 6/2/2014
Neurotez, Inc., GCA Therapeutics Strike $102.5 Million+ Alzheimer's Pact 5/21/2014
Ophthotech Corporation (OPHT) May Pocket $1 Billion From Eye Drug Deal With Novartis AG (NVS), Ophthotech Stock Up +24.48% At Market Close (May 20, 2014) 5/20/2014
AstraZeneca PLC (AZN) Rejects Pfizer Inc. (PFE)'s Final Offer 5/20/2014
Valeant Pharmaceuticals International (VRX) Will Sweeten $46 Billion Allergan Inc. (AGN) Bid 5/14/2014
Lundbeck Inc. (LUN.CO) Swallows Up Chelsea Therapeutics, Inc. (CHTP) In Deal Worth $658 Million 5/9/2014
Pfizer Inc. (PFE) Still Wants AstraZeneca PLC (AZN) After $98.7 Billion Bid Rejected 4/29/2014
Celgene Corporation (CELG) Antes Up $710 Million Upfront For Phase 3-Ready Crohn's Disease Drug 4/24/2014
Allergan Inc. (AGN) Curls Up Into Poison-Pill Position In Wake Of Valeant Pharmaceuticals International (VRX), Ackman Acquisition Bid 4/23/2014
FORMA Therapeutics, Inc. Picks Up Another $225 Million, And A Potential Buyout From Celgene (CELG) 4/2/2014
Baxter International, Inc. (BAX) To Split Into Two Companies, Spins Off $6 Billion Biotech Biz 3/28/2014
MedImmune (AZN), MD Anderson Cancer Center Agree To Launch Moon Shot At Cancer 3/20/2014
Five Prime Therapeutics, Inc. (FPRX), Bristol-Myers Squibb Company (BMY) Strike $350 Million Immuno-Oncology Pact 3/18/2014
Charles River Laboratories (Massachusetts) Shells Out $179 Million Cash To Buy Galapagos NV (GLPG.BR)'s CRO Services Division 3/13/2014
Top Biopharmas Such As Abbott Laboratories (ABT) And GlaxoSmithKline (GSK) Still Betting On "Messed Up" Indian Drugs Market 3/12/2014
Novartis AG (NVS) Chairman Rules Out Merger With Roche (RHHBY) 3/3/2014
Actavis (ACT) Bags Rival, Forest Laboratories, Inc. (FRX), For $25 Billion; Forest Stock Rockets +27.52% At Market Close (February 18, 2014) 2/19/2014
CoStim Pharmaceutical Buyout Bolsters Novartis AG (NVS)'s Cancer Portfolio 2/18/2014
Mallinckrodt Pharmaceuticals (MNK) Adds Pain Drug With $1.3 Billion Cash Cadence Pharmaceuticals, Inc. Buyout 2/11/2014
Eli Lilly and Company (LLY), Pfizer Inc. (PFE) And Eight Other Rivals Join The National Institutes of Health (NIH) In $230 Million Deal To Search For New Drugs 2/5/2014
Ablynx (ABLYF), Merck & Co., Inc. (MRK) Forge Cancer Pact Worth $2.3 Billion 2/3/2014
Nantbioscience Scores $75 Million Cancer Deal With Celgene Corporation (CELG) 1/16/2014
Regeneron Pharmaceuticals, Inc. (REGN), Bayer HealthCare (BAY) Forge Pact Worth $65 Million+ To Co-develop Wet AMD Drug 1/14/2014
Jazz Pharmaceuticals plc (JAZZ) Forges Pact Worth $397 Million For Aerial BioPharma's Sleepiness Drug 1/13/2014
Santaris Pharma A/S, Roche (RHHBY) Strike $148 Million+ Alliance To Design And Develop RNA-Targeted Drugs 1/10/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) May Pay Sangamo BioSciences, Inc. (SGMO) As Much As $320 Million For Blood Drugs; SGMA Soars +38.32% At Market Close (January 9, 2014) 1/9/2014
Roche (RHHBY) Inks Deal Worth Up To $600 Million For Prothena Corporation plc's Parkinson's Drug 12/13/2013
Biogen Idec, Inc. (Massachusetts) (BIIB), Proteostasis Therapeutics, Inc. Hammer Out $200 Million+ Pre-Clinical Alzheimer's Pact 12/9/2013
Celgene Corporation (CELG) Smacks Down $177 Million Upfront For OncoMed Pharmaceuticals, Inc. (OMED)'s Stem Cell Drugs, Deal Is Potentially Worth $3.3 Billion; OMED Stock Up 97.86% at Market Close (December 3, 2013) 12/4/2013
Roche (RHHBY), Molecular Partners AG Ink $1 Billion+ Cancer Pact 12/4/2013
AstraZeneca PLC (AZN) Said To Be Eyeing Forest Laboratories, Inc. (FRX) Takeover Bid 12/4/2013
immatics biotechnologies GmbH, Roche (RHHBY) Ink Cancer Pact Worth Up To $1 Billion 11/13/2013
ImmunoGen, Inc. (IMGN) Is On A Roll, Inks Fifth New License Agreement Of 2013 11/11/2013
Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated (VPHM) 11/11/2013
Salix Pharmaceuticals, Ltd. (SLXP) Bags Santarus Inc. (SNTS) for $2.6 Billion to Beef Up Gastro Drug Line-Up 11/8/2013
Roche (RHHBY) to Pay Polyphor Up to $548 Million for Superbug Antibiotic 11/4/2013
Amgen (AMGN) Acquires Filgrastim Franchise Rights From Roche (RHHBY) in 100 Markets 10/23/2013
Startup NextCODE Health, Launches Operations With $15 Million in Venture Financing 10/23/2013
PDL BioPharma, Inc. (PDLI) Snatches Up Depomed, Inc. (DEPO)'s Diabetes Portfolio for $240.5 Million 10/22/2013
AmpliPhi Biosciences (TGEN) Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies 10/17/2013
AstraZeneca PLC (AZN)'s MedImmune (AZN) Takes Over Spirogen Ltd. for Up to $400 Million to Bolster Oncolology Portfolio 10/15/2013
Ablynx (ABLYF) Scores $840 Million Inflammatory Drug Pact With AbbVie (ABBV); Ablynx Stock Rises 24.73% at Market Close (September 23, 2013) 9/23/2013
Clovis Oncology (CLVS) Looking to Sell Itself 9/18/2013
Roche (RHHBY), Inovio Pharmaceuticals (INO) Strike Vaccines Pact Worth $422.5 Million 9/11/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Makes $100 Million Upfront Payment in R&D Neurological Disorders Pact With Isis Pharmaceuticals, Inc. (ISIS) 9/9/2013
Japan's Otsuka Pharmaceutical Co., Ltd. Shells Out $886 Million for U.S. Cancer Firm Astex Pharmaceuticals (ASTX) 9/5/2013
Amgen (AMGN) Finally Reaches Deal to Buy Onyx Pharmaceuticals, Inc. (ONXX) for $10.4 Billion, AMGN Stock Rockets +7.72% on Monday @ Market Close (August 26, 2013) 8/26/2013
Shire plc Hires Adviser on Takeover Threat 8/20/2013
Adimab LLC. Adds Celgene Corporation (CELG) to Its Growing List of Big-Name Drugmaking Partners 8/20/2013
Array BioPharma, Inc. (ARRY) Says Amgen (AMGN) Ends Agreement, to Cut 20 Percent of Jobs 8/9/2013
Jazz Pharmaceuticals plc (JAZZ) and Alkermes plc (ALKS) are Seen as Next Targets Amid Irish Deal Frenzy: Real M&A 8/6/2013
Transition Therapeutics Inc. (TTH.TO) Buys Rights to Eli Lilly and Company (LLY)'s Arthritis Drug; Transition May be Eligible for $130 Million+ 7/24/2013
Pfizer Inc. (PFE) Not Moving Forward With Onyx Pharmaceuticals, Inc. (ONXX) Bid: Sources 7/19/2013
Quest Diagnostics Inc. (DGX) Sells Ibrutinib Royalty Rights to Royalty Pharma for $485 Million in Cash 7/18/2013
Spectrum Pharmaceuticals, Inc. (SPPI) Snaps Up Talon Therapeutics, Inc. (TLON.OB) in $206.3 Million Deal 7/17/2013
Array BioPharma, Inc. (ARRY), Loxo Oncology Strike $434 Million+ Cancer Pact 7/11/2013
AstraZeneca PLC (AZN) and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership 6/17/2013
Johnson & Johnson (JNJ) to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion 6/17/2013
Johnson & Johnson (JNJ) Sells Final Stake in Elan Corporation PLC (ELN) for $332 Million 6/14/2013
Cytokinetics, Inc. (CYTK), Amgen (AMGN) Expand $75 Million Development Deal Into Japan 6/12/2013
AstraZeneca PLC (AZN) in Deal for Pearl Therapeutics Worth Up to $1.15 Billion 6/11/2013
Actavis (ACT) Nabs Warner Chilcott, PLC (WCRX) for $8.5 Billion 5/20/2013
AbbVie (ABBV), Galapagos NV (GLPG.BR) Ink $50 Million Crohn's Disease Pact 5/17/2013
AstraZeneca PLC (AZN), Cubist Pharmaceuticals, Inc. (CBST), Astellas Pharma Inc. (YPH.BE) Said to Make Bids for Optimer Pharmaceuticals, Inc. (OPTR) 5/15/2013
Elan Corporation PLC (ELN) Bets $1 Billion on Theravance, Inc. (THRX) Drugs; Move to Spurn Its Hostile Suitor? 5/13/2013
Concert Pharmaceuticals, Inc. and Celgene Corporation (CELG) Tie the Knot in a $300 Million Tech Deal 5/6/2013
Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China 4/15/2013
GlaxoSmithKline (GSK) Targets "Electroceuticals" for Potential New Therapies 4/11/2013
GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical Engineering and Sciences to Develop New Medicines for Emerging Markets 4/9/2013
Resverlogix Corporation (RVX.TO) to Spin-Out RVX Therapeutics Inc. (RVX) 4/8/2013
Roche (RHHBY) and Isis Pharmaceuticals, Inc. (ISIS) Form $392 Million Alliance for Huntington's Disease 4/8/2013
AstraZeneca PLC (AZN) Shells Out $240 Million Upfront for Moderna Therapeutics mRNA Drugs 3/22/2013
bluebird bio Forms Cancer Drug Partnership With Celgene Corporation (CELG) 3/21/2013
Receptos Licenses AbbVie (ABBV) Antibody for Co-Development 3/14/2013
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors 3/13/2013
Presage Biosciences Snags $13 Million From Celgene Corporation (CELG) to Pick Winning Cancer Drug Combos 3/5/2013
Merck & Co., Inc. (MRK) and Samsung Corporation to Develop Biosimilar Drugs Together 2/20/2013
Roche (RHHBY) and Chiasma Inc. to Ally on Drug Development for Up to $600 Million 2/20/2013
RQx Pharmaceuticals, Inc. Inks $111 Million Genentech (RHHBY) Deal 2/12/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) to Buy Elan Corporation PLC (ELN)'s Tysabri Rights for $3.25 Billion 2/7/2013
The Medicines Company (MDCO) Buys Cholesterol Drug Rights From Alnylam Pharmaceuticals (ALNY) for Up to $205 Million 2/5/2013
Allergan Inc. (AGN) to Buy MAP Pharmaceuticals, Inc. (MAPP) for $958 Million 1/23/2013
Life Technologies (LIFE) Gains on Buyout Speculation 1/21/2013
Shire plc Rises on AstraZeneca PLC (AZN) Bid Talk: Traders 1/17/2013
MacroGenics, Inc.'s DART Platform Grabs Potential $1 Billion Gilead Sciences, Inc. (GILD) Deal 1/8/2013
Amgen (AMGN), BIND Biosciences, Inc. Ink $180 Million Tumor Treatment Deal 1/8/2013
Gilead Sciences, Inc. (GILD) Bags Blood Disorder Drug With $510 Million YM BioSciences (YM.TO) Buy 12/13/2012
Teva Pharmaceutical Industries Limited (TEVA) Enters $376 Million Deal for Xenon Pharmaceuticals Inc. Pain Drug 12/11/2012
Amgen (AMGN) Bags Gene-Hunting Firm deCODE genetics, Inc. (DCGN) for $415 Million Cash 12/11/2012
Biogen Idec, Inc. (Massachusetts) (BIIB), Isis Pharmaceuticals, Inc. (ISIS) in Drug Development Pact for Up to $630 Million 12/10/2012
Sanofi (France) (SAN.PA) Deal Could Net Selecta Biosciences, Inc. $900 Million 11/29/2012
Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK) Team Up to Form Clinical Trial Site Database 11/15/2012
Forest Laboratories, Inc. (FRX) and Adamas Pharmaceuticals Form Alliance for Up to $160 Million 11/14/2012
Foundation Medicine and AstraZeneca PLC (AZN) Announce Genomic Profiling Collaboration 11/12/2012
Takeda Pharmaceutical Co. Ltd. (TKPYY) Shells Out $140 Million for Envoy Therapeutics 11/6/2012
Amgen (AMGN) Closes Deal With Financial Firm to Open New Biotech Company Atara Biotherapeutics 10/29/2012
Pfizer Inc. (PFE) Will Buy NextWave Pharmaceuticals for Up to $680 Million 10/23/2012
Theravance, Inc. (THRX), Merck & Co., Inc. (MRK) Ink $153 Million Cardiovascular Pact 10/16/2012
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/16/2012
AstraZeneca PLC (AZN) Boosts Pipeline With $272 Million Ardelyx Inc. Drug Deal 10/9/2012
Evotec AG (EVTG.F) and Bayer AG (BAY.F) Enter Into $765 Million Multi-Target Alliance to Fight Endometriosis 10/1/2012
MacroGenics, Inc. Could Earn More Than $1 Billion Through New Servier Alliance 9/20/2012
Baxter International, Inc. (BAX) and Onconova Therapeutics Inc. Announce European Licensing Agreement for Up to $515 Million 9/19/2012
Complete Genomics, Inc. to be Bought by Chinese Firm for $117.6 Million 9/17/2012
AstraZeneca PLC (AZN)'s MedImmune (AZN) Forms Chinese Joint Venture for Biologic Drug 9/11/2012
Genmab A/S (GEN.CO) Inks $1.1 Billion Deal With Johnson & Johnson (JNJ) 8/31/2012
Allergan Inc. (AGN), Molecular Partners AG Ink $1.5 Billion Exclusive Pact 8/21/2012
AstraZeneca PLC (AZN) Buys Into Regulus Therapeutics, Inc.' MicroRNA Therapeutics for $28 Million 8/15/2012
Elan Corporation PLC (ELN) Fuels Buyout Plans With $130 Million R&D Spinout, Unit Will Have Around 80 Staffers 8/14/2012
S*Bio of Singapore Sells Cancer Drug Rights to MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) for $75 Million 8/10/2012
GlaxoSmithKline (GSK) Completes $3.6 Billion Takeover of Human Genome Sciences, Inc. (HGSI) 8/6/2012
Life Technologies (LIFE) Buys Navigenics for Genetic Diagnostics 7/17/2012
GlaxoSmithKline (GSK) Clinches Deal to Buy Human Genome Sciences, Inc. (HGSI) for $2.8 Billion 7/16/2012
Alnylam Pharmaceuticals (ALNY), Ascletis, Inc. Create Strategic Collaboration to Develop ALN-VSP 7/12/2012
Verastem, Inc. (VSTM) Buys Pfizer Inc. (PFE) Cancer Drug Candidate in Deal Worth $126.5 Million 7/12/2012
AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Join Forces in $7 Billion Deal for Amylin Pharmaceuticals, Inc. (AMLN) 7/3/2012
AstraZeneca PLC (AZN), Rigel Pharmaceuticals, Inc. (RIGL) Strike Potential $100 Million Asthma Drug Deal 6/19/2012
Roche (RHHBY)'s Genentech (RHHBY) Grabs Alzheimer's Drug Rights From AC Immune SA for $418 Million-Plus 6/19/2012
GlaxoSmithKline (GSK) Rumored to be Buying $5 Billion BioMarin Pharmaceutical Inc. (BMRN) 6/13/2012
GlaxoSmithKline (GSK) Pays $227 Million for Basilea Pharmaceutica (BSLN.SW) Eczema Drug 6/12/2012
AstraZeneca PLC (AZN) Bids $4 Billion for Diabetes Specialist Amylin Pharmaceuticals, Inc. (AMLN) 6/5/2012
Basilea Pharmaceutica (BSLN.SW) Participates in Public-private Collaboration to Tackle Antibiotic Resistance 5/25/2012
Agilent Technologies Inc. (A) to Acquire Dako North America, Inc. for $2.2 Billion 5/17/2012
GlaxoSmithKline (GSK)'s $2.6 Billion Bid for Human Genome Sciences, Inc. (HGSI) Goes Hostile 5/10/2012
Novartis AG (NVS) Snags Fougera (AAA) for $1.5 Billion for Generic Skin Drugs 5/3/2012
Axerion Therapeutics Inc., AstraZeneca PLC (AZN) Inks Pact to Combat Alzheimer's Disease 5/2/2012
Amylin Pharmaceuticals, Inc. (AMLN) Explores Sale, Hires Bankers: Sources; Is AstraZeneca PLC (AZN) Interested? 4/24/2012
AstraZeneca PLC (AZN) to Acquire Ardea Biosciences, Inc. for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout 4/23/2012
Human Genome Sciences, Inc. (HGSI) Rejects GlaxoSmithKline (GSK)'s $2.6 Billion Bid, Seeks Higher Offers 4/20/2012
Roche (RHHBY) Ready to Walk Away From $6.8 Billion Illumina, Inc. (ILMN) Bid 4/19/2012
Amgen (AMGN) to Pay $315 Million for Privately-Held KAI Pharmaceuticals, Inc. 4/11/2012
Watson Pharmaceuticals, Inc. (WPI) Close to $7 Billion Actavis Drug Deal: Sources 3/22/2012
Heptares Grants Shire plc an Exclusive Worldwide $190 Million License to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3/20/2012
BioCon Limited (BIOCON.NS) Plunges After Pfizer Inc. (PFE) Scraps $350 Million Insulin Pact 3/14/2012
EpiStem Ltd Announces a Three Year Collaboration With GlaxoSmithKline (GSK) in Fibrosis Research 3/13/2012
Mersana Therapeutics, Inc. Strikes $270 Million Antibody-drug Conjugate Deal With Endo Pharmaceuticals (ENDP) 3/7/2012
AngioChem, GlaxoSmithKline (GSK) Form $331 Million Pact to Discover and Develop Treatments of Lysosomal Storage Diseases 2/27/2012
Enanta Pharmaceuticals, Inc. Strikes Hep C Drug Deal With Novartis AG (NVS) Worth Up to $440 Million 2/22/2012
Pfizer Inc. (PFE) Eyes Tie-Ups With More Chinese Drugmakers; Will Ally With Zhejiang Hisun to Invest $545 Million in Generic Drug JV 2/21/2012
Roche (RHHBY) Digs in for Long Fight as Illumina, Inc. (ILMN) Rejects $5.7 Billion Bid 2/10/2012
Merck KGaA (MKGAF.PK) Signs $550 Million Cancer Pact With Threshold Pharmaceuticals, Inc. (THLD) 2/3/2012
Genentech (RHHBY) Pours $95 Million into Constellation Pharmaceuticals Epigenetic Drug Platform, Deal Includes M&A Terms 1/17/2012
Roche (RHHBY) Signs $646 Million Pain Pact With Xenon Pharmaceuticals Inc. 1/10/2012
Bristol-Myers Squibb Company (BMY) to Acquire Inhibitex, Inc. (INHX) for $2.5 Billion 1/9/2012
FORMA Therapeutics, Inc. Cuts $815 Million Deal With Boehringer Ingelheim Corporation to Discover Cancer Drugs 1/5/2012
Alexion Pharmaceuticals Inc. (ALXN) to Pay $1 Billion for Enobia Pharma 12/29/2011
Pharmacyclics, Inc. (PCYC) Could Get $975 Million in Johnson & Johnson (JNJ) License Deal 12/9/2011
AstraZeneca PLC (AZN) Digs Deeper in China With Generics Buy 12/8/2011
Biogen Idec, Inc. (Massachusetts) (BIIB) Teams With Samsung Corporation on $300 Million Biosimilar Venture 12/6/2011
MacroGenics, Inc. Inks Pharma Deal With Servier Worth Up to $450 Million 12/1/2011
Roche (RHHBY) and PTC Therapeutics, Inc. Sign $490 Million Deal for Genetic Disease Program 11/29/2011
Gilead Sciences, Inc. (GILD) to Acquire Pharmasset, Inc. (VRUS) for $11 Billion 11/22/2011
AMAG Pharmaceuticals, Inc. (AMAG) Hires Jefferies and Co. to Explore Sale 11/17/2011
Gilead Sciences, Inc. (GILD) and Johnson & Johnson (JNJ)'s Tibotec Pharmaceuticals Ltd to Create Combination HIV Therapy 11/16/2011
Lundbeck Inc. Pays Otsuka Pharmaceutical Co., Ltd. $200 Million Upfront in CNS Drug Deal, Complete Deal is Worth $1.8 Billion if Milestones are Met 11/14/2011
Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Company (LLY) End Bydureon Pact; Amylin to Make $1.45 Billion in Payments 11/8/2011
Abbott Laboratories (ABT) to Split Into 2 Companies 10/21/2011
GlaxoSmithKline (GSK) May Make $4.8 Billion Bid for Human Genome Sciences, Inc. (HGSI): Source 10/19/2011
Roche (RHHBY) Buys Anadys Pharmaceuticals, Inc. (ANDS) for $230 Million to Boost Hepatitis Ops 10/17/2011
GlycoMimetics, Inc. Inks Licensing Deal Worth Up to $340 Million with Pfizer Inc. (PFE) 10/11/2011
PPD, Inc. (PPDI) to be Acquired by The Carlyle Group and Hellman & Friedman for $3.9 Billion 10/4/2011
Bristol-Myers Squibb Company (BMY) and Ambrx, Inc. Announce $24 Million Collaboration for Novel Biologics Programs in Diabetes and Heart Failure 9/22/2011
Roche (RHHBY), Evotec AG (EVTG.F) Sign Alzheimer's Pact Worth Up to $830 Million 9/7/2011
f-Star, Merck Serono Sign $708 Million Deal for Antibody-Derived Therapeutics 9/7/2011
Astellas Pharma Inc. (YPH.BE), Evec Team Up for Antibody Pact Worth Up to $176.8 Million 9/6/2011
Sanofi (France) (SASY.PA) Strikes Deal With Pfizer Inc. (PFE) to Make Generic Lipitor 9/1/2011
Carlyle Group in Talks to Buy PPD, Inc. (PPDI) for as Much as $4.3 Billion 8/17/2011
QIAGEN N.V. (QGEN) and Pfizer Inc. (PFE) Partner to Develop Companion Diagnostic for Novel Compound in Global Clinical Trials for Lung Cancer 8/16/2011
4-Antibody AG Forms Collaboration with Human Genome Sciences, Inc. (HGSI) 8/16/2011
AMAG Pharmaceuticals, Inc. (AMAG) Investor MSMB Makes $378 Million Takeover Bid for Firm to Stop Merger With Allos Therapeutics, Inc. (ALTH) 8/3/2011
Bristol-Myers Squibb Company (BMY) to Pay Up to $475 Million for Amira Pharmaceuticals, Inc., Scoops Up Lung Drug 7/22/2011
Novartis AG Ends Pursuit of Gen-Probe Incorporated (GPRO) 7/22/2011
AMAG Pharmaceuticals, Inc. (AMAG), Allos Therapeutics, Inc. (ALTH) to Merge in $686 Million Deal 7/20/2011
Micromet Inks Cancer Drug Deal With Amgen (AMGN) Worth Up to $1.01 Billion 7/12/2011
Bristol-Myers Squibb Company (BMY), Innate Pharma (IPH.PA ) Announce $465 Million Deal for an Investigational Immuno-Oncology Biologic; Innate to Receive $35 Million Upfront, Shares Soar 7/7/2011
Vertex Pharmaceuticals (MA) (VRTX) in Licensing Pact Potentially Worth $1.5 Billion With Alios BioPharma to Expand Hepatitis Pipeline 6/13/2011
Merck & Co., Inc. (MRK) Buys Hanwha Drug-Marketing Rights for $720 Million 6/13/2011
Merck & Co., Inc. (MRK), Roche (RHHBY) Pair Up on Tests for Cancer Treatments 6/7/2011
Clovis Oncology (CLVS) Receives License for Worldwide Development and Commercialization Rights to Pfizer Inc. (PFE)'s Oral and IV PARP Inhibitor PF-01367338 6/3/2011
AVEO Pharmaceuticals, Inc. (AVEO) Enters into Worldwide License Agreement with Centocor Ortho Biotech Products, L.P.; AVEO Receives $15 Million; Eligible for up to $540 Million 5/31/2011
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Nails Nycomed Buyout for $13.7 Billion, Skin Unit to Spin Off 5/19/2011
Allos Therapeutics, Inc. (ALTH) and Mundipharma AG Announce Strategic Collaboration for FOLOTYN; Allos to Receive $50 Million Upfront; Potentially up to $310.5 Million 5/11/2011
Alkermes (ALKS), Elan Drug Technologies in $960 Million Merger 5/9/2011
Teva Pharmaceutical Industries Limited (TEVA) to Buy Japanese Generic Drugmaker, Taiyo Pharmaceuticals Industry Co. Ltd. for $490 Million 5/3/2011
Teva Pharmaceutical Industries Limited (TEVA) to Buy Cephalon, Inc. (CEPH) for Over $6 Billion, Tops Valeant Pharmaceuticals International (VRX) 5/2/2011
Sanofi-Aventis (Canada) Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 4/18/2011
Exelixis, Inc. (EXEL) Said to Hire Goldman, Sachs & Co. to Field Possible Takeover Approaches; Shares Rise on Speculation 4/12/2011
Zacharon Pharmaceuticals, Inc. Announces Potential $200 Million Collaboration With Pfizer Inc. (PFE) to Develop Drugs for Multiple Rare Disorders 4/7/2011
Cephalon, Inc. (CEPH) Spurns Valeant Pharmaceuticals International (VRX)'s $5.7 Billion Hostile Bid as Too Low 4/6/2011
Merck & Co., Inc. (MRK) to Acquire Inspiration Biopharmaceuticals for $430 Million 4/6/2011
Seattle Genetics, Inc. (SGEN) Announces Antibody-Drug Conjugate Collaboration with Abbott Laboratories (ABT); Seattle Genetics Gets $8 Million Upfront; Eligible for as much as $200 Million 3/22/2011